pharma · Acute Myeloid Leukemia · Advanced Hematologic Malignancy · FHTX
Foghorn Therapeutics
Foghorn Therapeutics is a pharma organization headquartered in Watertown, USA. It trades on NYSE under ticker FHTX. Primary therapeutic focus areas include Acute Myeloid Leukemia, Advanced Hematologic Malignancy, Metasta
Watertown, USA HQ
2016 Founded
124 Employees
Public company Type
FHTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Watertown, USA
- Founded
- 2016
- Employees
- 124
- Programs
- 5
- Drugs
- 2
- Patents
- 14
FHD-609
Phase 1 · small molecule · Advanced Synovial Sarcoma
FHD-609 for Advanced Synovial Sarcoma is a Phase 1 program (small_molecule) at Foghorn Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code FHD-609-C-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Foghorn Therapeutics
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Advanced Synovial Sarcoma
- Status
- terminated
- Trials
- 1